Scancell Holdings plc, the developer of novel immunotherapy products for the treatment of multiple cancers, announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company’s Phase 2 clinical SCOPE study. This cohort will evaluate intradermal administration of Scancell’s iSCIB1+, potent, targeted “off-the-shelf” Immunobody® second generation DNA cancer vaccine. Source: Scancell press release 14/4/2025